Orgenesis to establish new facility for cell, gene therapy manufacturing
Orgenesis announced plans to establish a new production site for its Masthercell Global subsidiary, designed to manufacture late-stage and commercially-approved cell and gene therapy products. The company signed a lease agreement for a 5,700 square meter building located within the Gosselies Biopark in Belgium. The new commercial facility is expected to be operational early in 2021 and is expected to triple Masthercell Global's current capacity. The facility will include industry 4.0 precepts such as software integration, intelligent equipment and integrated processes with the objective to provide cell and gene therapy customers an efficient and cost-effective manufacturing solution. Once the new commercial facility is operational, the current facility, also located within the Gosselies Biopark, will instead focus on industrial manufacturing process development and early to mid-stage, clinically-focused cell and gene therapy products.